Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Fischer

Showing results (41-50 of 493) with videos related to

Pageof 50
Sort By:
Current Opinion in Rheumatology|June 24, 2003
Defective cytotoxic granule-mediated cell death pathway impairs T lymphocyte homeostasisGeneviève de Saint Basile, Alain Fischer
Advances in Immunology|February 21, 2004
Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes)Anne Durandy, Patrick Revy, Alain Fischer
The Journal of Experimental Medicine|December 12, 2019
Gene therapy for severe combined immunodeficiencies and beyondAlain Fischer, Salima Hacein-Bey-Abina
Medecine Sciences : M/S|November 30, 2022
[Therapeutic innovation for the common good]Michel Goldman, Mathias Dewatripont, Alain Fischer
La Revue Du Praticien|December 18, 2007
[Immunologic deficiencies. Optimizing diagnostic and therapeutic approaches]Olivier Lortholary, Alain Fischer, Olivier Hermine
Plos Medicine|August 18, 2005
The European rare diseases therapeutic initiativeAlain Fischer, Pascale Borensztein, Claire Roussel
Current Opinion in Rheumatology|June 10, 2006
Hyper-IgM syndromesAnne Durandy, Sophie Peron, Alain Fischer
Current Opinion in Allergy and Clinical Immunology|November 13, 2003
Hyper-immunoglobulin-M syndromes caused by an intrinsic B cell defectAnne Durandy, Patrick Revy, Alain Fischer
Nature Medicine|November 27, 2019
Benefit Corporation: a path to affordable gene therapies?Alain Fischer, Mathias Dewatripont, Michel Goldman
Medecine Sciences : M/S|May 2, 2020
[What is the fair price of innovative therapy?]Alain Fischer, Mathias Dewatripont, Michel Goldman
Pageof 50

Showing results (41-50 of 493) with videos related to

Sort By:
Pageof 50
Current Opinion in Rheumatology|June 24, 2003
Defective cytotoxic granule-mediated cell death pathway impairs T lymphocyte homeostasisGeneviève de Saint Basile, Alain Fischer
Advances in Immunology|February 21, 2004
Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes)Anne Durandy, Patrick Revy, Alain Fischer
The Journal of Experimental Medicine|December 12, 2019
Gene therapy for severe combined immunodeficiencies and beyondAlain Fischer, Salima Hacein-Bey-Abina
Medecine Sciences : M/S|November 30, 2022
[Therapeutic innovation for the common good]Michel Goldman, Mathias Dewatripont, Alain Fischer
La Revue Du Praticien|December 18, 2007
[Immunologic deficiencies. Optimizing diagnostic and therapeutic approaches]Olivier Lortholary, Alain Fischer, Olivier Hermine
Plos Medicine|August 18, 2005
The European rare diseases therapeutic initiativeAlain Fischer, Pascale Borensztein, Claire Roussel
Current Opinion in Rheumatology|June 10, 2006
Hyper-IgM syndromesAnne Durandy, Sophie Peron, Alain Fischer
Current Opinion in Allergy and Clinical Immunology|November 13, 2003
Hyper-immunoglobulin-M syndromes caused by an intrinsic B cell defectAnne Durandy, Patrick Revy, Alain Fischer
Nature Medicine|November 27, 2019
Benefit Corporation: a path to affordable gene therapies?Alain Fischer, Mathias Dewatripont, Michel Goldman
Medecine Sciences : M/S|May 2, 2020
[What is the fair price of innovative therapy?]Alain Fischer, Mathias Dewatripont, Michel Goldman
Pageof 50